Insights
Search Results
Client Highlights
4.27.26
Wilson Sonsini Advises Nervonik on $52.5 Million Series B Financing
On April 27, 2026, Nervonik, a clinical-stage medical device company developing next-generation peripheral nerve stimulation (PNS) technologies, announced the closing of an oversubscribed $52.5 million Series B financing. The round was led by Amzak Health, with participation from Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, Foothill Ventures, and Shangbay Capital. The proceeds from the financing will support the continued development and commercialization of Nervonik's PNS system, including further development of its proprietary sensing capabilities. Wilson Sonsini Goodrich & Rosati advised Nervonik on the transaction.
Client Highlights
12.08.25
Wilson Sonsini Advises Foresight Diagnostics on Acquisition by Natera
On December 5, 2025, Natera, Inc., a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, announced that Natera has completed its acquisition of Foresight in an all-stock transaction consisting of a $275 million upfront payment with an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones. Wilson Sonsini Goodrich & Rosati advised Foresight on the transaction.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
Client Highlights
5.21.25
Wilson Sonsini Advises Halo Labs on Acquisition by Waters
On May 21, 2025, Waters Corporation announced that it acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. Wilson Sonsini Goodrich & Rosati advised Halo Labs on the transaction.
Client Highlights
12.18.23
Wilson Sonsini Advises Visant Medical on Acquisition By Nordic Pharma
On December 18, 2023, Amring Pharmaceuticals Inc., a subsidiary of Nordic Group B.V. (Nordic Pharma), announced the completion of its acquisition of Visant Medical, Inc., a leader in medical technology innovation in Dry Eye Disease (DED). Wilson Sonsini Goodrich & Rosati advised Visant Medical on the transaction.